Research programme: chronic obstructive pulmonary disease therapy - CereMedix
Latest Information Update: 12 Jul 2007
At a glance
- Originator CereMedix
- Mechanism of Action Antioxidants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 01 Jul 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (unspecified route)